-
Mashup Score: 0Monoclonal Gammopathy of Renal Significance | NEJM - 3 year(s) ago
Review Article from The New England Journal of Medicine — Monoclonal Gammopathy of Renal Significance
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Onco-Nephrology Program - 3 year(s) ago
Roman Shingarev, MD, joins the Cancer Advances podcast to discuss Cleveland Clinic’s new onco-nephrology program.
Source: Cleveland ClinicCategories: Hem/Oncs, Latest HeadlinesTweet-
Onco-Nephrology Program #nephroonc https://t.co/tYe8EI0NRv via @clevelandclinic
-
-
Mashup Score: 2Monoclonal Gammopathy of Renal Significance | NEJM - 3 year(s) ago
Review Article from The New England Journal of Medicine — Monoclonal Gammopathy of Renal Significance
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Monoclonal Gammopathy of Renal Significance (MGRS) [May 20, 2021] Leung, Bridoux, & Nasr @NEJM https://t.co/4oBHr51zLF #mmsm #onconeph #nephroonc #Nephpearls #NephTwitter #MayoClinicKidney
-
-
Mashup Score: 2Monoclonal Gammopathy of Renal Significance | NEJM - 3 year(s) ago
Review Article from The New England Journal of Medicine — Monoclonal Gammopathy of Renal Significance
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Monoclonal Gammopathy of Renal Significance (MGRS) [May 20, 2021] Leung, Bridoux, & Nasr @NEJM https://t.co/4oBHr51zLF #mmsm #onconeph #nephroonc #Nephpearls #NephTwitter #MayoClinicKidney https://t.co/1fpPQx6A30
-
-
Mashup Score: 0
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy [Jun 23, 2020] Bridoux et al. JCO @ASCO_pubs https://t.co/O9uteG4QXh #mmsm #onconeph #nephroonc n=186 NDMM w/ AKI not on HD https://t.co/0wiVoU2blR
-
-
Mashup Score: 0
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy [Jun 23, 2020] Bridoux et al. JCO @ASCO_pubs https://t.co/O9uteG4QXh #mmsm #onconeph #nephroonc n=186 NDMM w/ AKI not on HD https://t.co/3EqSOUlCMV
-
-
Mashup Score: 1
It is not known how frequently a kidney biopsy specimen reveals monoclonal gammopathy (MG) of renal significance (MGRS) in patients with MG or what factors predict this finding. In a review of medical records of 6300 patients with MG, the authors found that only 160 (2.5%) had a biopsy. Of those, 96 (60%) had lesions unrelated to MG, with arteriosclerosis and diabetic nephropathy accounting for…
Source: American Society of NephrologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Rate & Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Pts w/ MGUS [August 2020] Klomjit, Leung @fervenzafernan1 @SethiRenalPath @LadanZand @JASN_News https://t.co/zfuPySn5u9 #Nephpearls #NephTwitter #mmsm #onconeph #nephroonc https://t.co/FvG8PWnh06
-
-
Mashup Score: 0
Key Points. Carfilzomib+dexamethasone (Kd) had significantly higher renal overall and complete response vs bortezomib+dex (Vd) in a real-world study.In a combin
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Renal response in real-world carfilzomib- vs bortezomib-treated RRMM [Jan 19, 2021] @myelomaMD et al. @BloodAdvances https://t.co/wsDCtp9ZD9 #mmsm #onconeph #nephroonc RWE Kd > Vd in RRMM renal rescue & positive association b/w renal response & improved survival
-
-
Mashup Score: 0Validate User - 3 year(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your content.
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Renal response in real-world carfilzomib- vs bortezomib-treated RRMM [Jan 19, 2021] @myelomaMD et al. @BloodAdvances https://t.co/wsDCtp9ZD9 #mmsm #onconeph #nephroonc RWE Kd > Vd in RRMM renal rescue & positive association b/w renal response & improved survival https://t.co/2RSvxu1bXn
-
-
Mashup Score: 2
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy [Jun 23, 2020] Bridoux et al. JCO @ASCO_pubs https://t.co/O9uteG4QXh #mmsm #onconeph #nephroonc n=186 NDMM w/ AKI not on HD https://t.co/IennXmShxM
-
Monoclonal Gammopathy of Renal Significance (MGRS) [May 20, 2021] Leung, Bridoux, & Nasr @NEJM https://t.co/4oBHr51zLF #mmsm #onconeph #nephroonc #Nephpearls #NephTwitter #MayoClinicKidney